Bioequivalency, FDA Approval, Gene Therapy and Marketing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioequivalency

FDA Approval

Gene Therapy

Marketing

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

DECEMBER 13, 2021

Both the FDA’s Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER) have regulatory responsibility for therapeutic biological products, which are subject to both the Federal Food, Drug and Cosmetic (FD & C) Act and the Public Health Service (PHS) Act. Product Type-Specific Analysis.

Development

Development Production Immune Response Licensing

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Worldwide Clinical Trials

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. Initial approval in 2022: FDA, U.S.

Gene

Gene Clinical Trials Clinical Trials Gene Therapy

Clinical Research Informer

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Stay Connected